Geron (GERN) Net Margin (2010 - 2026)

Geron (GERN) posted Net Margin of 6.88% for Q1 2026, down 131.56% sequentially from 21.81% in Q4 2025, and up 4299.0% YoY from 0.16% in Q1 2025.

Geron (GERN) Net Margin (2010 - 2026) Analysis & Trends

Geron has reported Net Margin for 17 years, with the latest figure at 6.88% in Q1 2026.

Quarterly Net Margin rose 4299.0% year-over-year to 6.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 416.22% (down 7185.0% YoY) and the FY2025 annual result came in at 12863.55%, up 10417813.0% from the prior year.
Net Margin retreated to 6.88% in Q1 2026 per GERN's latest filing, from 21.81% in the prior quarter.
Over five years, Net Margin peaked at 23700.47% in Q4 2023 and troughed at 181719.05% in Q1 2023.
A 5-year average of 29382.91% and a median of 7632.65% in 2024 frame the typical range for Net Margin.
The sharpest annual moves came in 2023 and 2024: Net Margin tumbled 15676539 bps in 2023, then jumped 16351905 bps in 2024.
Over 5 years, Net Margin stood at 39799.03% in 2022, then soared by 160 bps to 23700.47% in 2023, then tumbled by 100 bps to 81.49% in 2024, then tumbled by 73 bps to 21.81% in 2025, then slumped by 132 bps to 6.88% in 2026.
According to Business Quant data, Net Margin over the past three periods registered 6.88%, 21.81%, and 38.68% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	139.50 Bn	131.65 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	86.10 Bn	78.10 Bn	3.93 Bn	30.23%
3	Argenx Se	65.59 Bn	60.41 Bn	1.37 Bn	31.16%
4	Moderna	56.75 Bn	51.62 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn	12.74%
7	BioNTech SE	27.80 Bn	9.41 Bn	668.28 Mn	-16.51%
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	-3.12%
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	12.09%
10	Geron	1.02 Mn	-299.83 Mn	-	-29.00%

Download Data